A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer. Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., Hiller, W., Fisher, E. R., Wickerham, D. L., Bryant, J., & Wolmark, N. New England Journal of Medicine, 351(27):2817--2826, 2004. ![A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex Over the past two decades, the molecular dissection of cancer has increased our understanding of the pathways that are altered in neoplastic cells.1,2 Nevertheless, the diagnosis of cancer and decisions about its treatment still rely largely on classic histopathological and immunohistochemical techniques. A more quantitative approach to diagnosis and rational individualization of treatment are needed. Large clinical trials, such as National Surgical Adjuvant Breast and Bowel Project (NSABP) trials B-14 and B-20, have demonstrated the benefit of tamoxifen and chemotherapy in women who have node-negative, estrogen-receptor–positive breast cancer.3–5 However, since the likelihood of distant recurrence in patients treated . . .
@article{paik_multigene_2004,
title = {A {Multigene} {Assay} to {Predict} {Recurrence} of {Tamoxifen}-{Treated}, {Node}-{Negative} {Breast} {Cancer}},
volume = {351},
issn = {0028-4793},
url = {http://www.nejm.org/doi/full/10.1056/NEJMoa041588},
doi = {10.1056/NEJMoa041588},
abstract = {Over the past two decades, the molecular dissection of cancer has increased our understanding of the pathways that are altered in neoplastic cells.1,2 Nevertheless, the diagnosis of cancer and decisions about its treatment still rely largely on classic histopathological and immunohistochemical techniques. A more quantitative approach to diagnosis and rational individualization of treatment are needed. Large clinical trials, such as National Surgical Adjuvant Breast and Bowel Project (NSABP) trials B-14 and B-20, have demonstrated the benefit of tamoxifen and chemotherapy in women who have node-negative, estrogen-receptor–positive breast cancer.3–5 However, since the likelihood of distant recurrence in patients treated . . .},
number = {27},
urldate = {2013-04-12},
journal = {New England Journal of Medicine},
author = {Paik, Soonmyung and Shak, Steven and Tang, Gong and Kim, Chungyeul and Baker, Joffre and Cronin, Maureen and Baehner, Frederick L. and Walker, Michael G. and Watson, Drew and Park, Taesung and Hiller, William and Fisher, Edwin R. and Wickerham, D. Lawrence and Bryant, John and Wolmark, Norman},
year = {2004},
pmid = {15591335},
pages = {2817--2826},
file = {Full Text PDF:files/38197/Paik et al. - 2004 - A Multigene Assay to Predict Recurrence of Tamoxif.pdf:application/pdf}
}
Downloads: 0
{"_id":"k4eEFxuzkLmR4jCkn","bibbaseid":"paik-shak-tang-kim-baker-cronin-baehner-walker-etal-amultigeneassaytopredictrecurrenceoftamoxifentreatednodenegativebreastcancer-2004","downloads":0,"creationDate":"2016-09-09T06:27:31.713Z","title":"A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer","author_short":["Paik, S.","Shak, S.","Tang, G.","Kim, C.","Baker, J.","Cronin, M.","Baehner, F. L.","Walker, M. G.","Watson, D.","Park, T.","Hiller, W.","Fisher, E. R.","Wickerham, D. L.","Bryant, J.","Wolmark, N."],"year":2004,"bibtype":"article","biburl":"https://www.sfu.ca/~howlett/howlett16.bib","bibdata":{"bibtype":"article","type":"article","title":"A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer","volume":"351","issn":"0028-4793","url":"http://www.nejm.org/doi/full/10.1056/NEJMoa041588","doi":"10.1056/NEJMoa041588","abstract":"Over the past two decades, the molecular dissection of cancer has increased our understanding of the pathways that are altered in neoplastic cells.1,2 Nevertheless, the diagnosis of cancer and decisions about its treatment still rely largely on classic histopathological and immunohistochemical techniques. A more quantitative approach to diagnosis and rational individualization of treatment are needed. Large clinical trials, such as National Surgical Adjuvant Breast and Bowel Project (NSABP) trials B-14 and B-20, have demonstrated the benefit of tamoxifen and chemotherapy in women who have node-negative, estrogen-receptor–positive breast cancer.3–5 However, since the likelihood of distant recurrence in patients treated . . .","number":"27","urldate":"2013-04-12","journal":"New England Journal of Medicine","author":[{"propositions":[],"lastnames":["Paik"],"firstnames":["Soonmyung"],"suffixes":[]},{"propositions":[],"lastnames":["Shak"],"firstnames":["Steven"],"suffixes":[]},{"propositions":[],"lastnames":["Tang"],"firstnames":["Gong"],"suffixes":[]},{"propositions":[],"lastnames":["Kim"],"firstnames":["Chungyeul"],"suffixes":[]},{"propositions":[],"lastnames":["Baker"],"firstnames":["Joffre"],"suffixes":[]},{"propositions":[],"lastnames":["Cronin"],"firstnames":["Maureen"],"suffixes":[]},{"propositions":[],"lastnames":["Baehner"],"firstnames":["Frederick","L."],"suffixes":[]},{"propositions":[],"lastnames":["Walker"],"firstnames":["Michael","G."],"suffixes":[]},{"propositions":[],"lastnames":["Watson"],"firstnames":["Drew"],"suffixes":[]},{"propositions":[],"lastnames":["Park"],"firstnames":["Taesung"],"suffixes":[]},{"propositions":[],"lastnames":["Hiller"],"firstnames":["William"],"suffixes":[]},{"propositions":[],"lastnames":["Fisher"],"firstnames":["Edwin","R."],"suffixes":[]},{"propositions":[],"lastnames":["Wickerham"],"firstnames":["D.","Lawrence"],"suffixes":[]},{"propositions":[],"lastnames":["Bryant"],"firstnames":["John"],"suffixes":[]},{"propositions":[],"lastnames":["Wolmark"],"firstnames":["Norman"],"suffixes":[]}],"year":"2004","pmid":"15591335","pages":"2817--2826","file":"Full Text PDF:files/38197/Paik et al. - 2004 - A Multigene Assay to Predict Recurrence of Tamoxif.pdf:application/pdf","bibtex":"@article{paik_multigene_2004,\n\ttitle = {A {Multigene} {Assay} to {Predict} {Recurrence} of {Tamoxifen}-{Treated}, {Node}-{Negative} {Breast} {Cancer}},\n\tvolume = {351},\n\tissn = {0028-4793},\n\turl = {http://www.nejm.org/doi/full/10.1056/NEJMoa041588},\n\tdoi = {10.1056/NEJMoa041588},\n\tabstract = {Over the past two decades, the molecular dissection of cancer has increased our understanding of the pathways that are altered in neoplastic cells.1,2 Nevertheless, the diagnosis of cancer and decisions about its treatment still rely largely on classic histopathological and immunohistochemical techniques. A more quantitative approach to diagnosis and rational individualization of treatment are needed. Large clinical trials, such as National Surgical Adjuvant Breast and Bowel Project (NSABP) trials B-14 and B-20, have demonstrated the benefit of tamoxifen and chemotherapy in women who have node-negative, estrogen-receptor–positive breast cancer.3–5 However, since the likelihood of distant recurrence in patients treated . . .},\n\tnumber = {27},\n\turldate = {2013-04-12},\n\tjournal = {New England Journal of Medicine},\n\tauthor = {Paik, Soonmyung and Shak, Steven and Tang, Gong and Kim, Chungyeul and Baker, Joffre and Cronin, Maureen and Baehner, Frederick L. and Walker, Michael G. and Watson, Drew and Park, Taesung and Hiller, William and Fisher, Edwin R. and Wickerham, D. Lawrence and Bryant, John and Wolmark, Norman},\n\tyear = {2004},\n\tpmid = {15591335},\n\tpages = {2817--2826},\n\tfile = {Full Text PDF:files/38197/Paik et al. - 2004 - A Multigene Assay to Predict Recurrence of Tamoxif.pdf:application/pdf}\n}\n\n","author_short":["Paik, S.","Shak, S.","Tang, G.","Kim, C.","Baker, J.","Cronin, M.","Baehner, F. L.","Walker, M. G.","Watson, D.","Park, T.","Hiller, W.","Fisher, E. R.","Wickerham, D. L.","Bryant, J.","Wolmark, N."],"key":"paik_multigene_2004","id":"paik_multigene_2004","bibbaseid":"paik-shak-tang-kim-baker-cronin-baehner-walker-etal-amultigeneassaytopredictrecurrenceoftamoxifentreatednodenegativebreastcancer-2004","role":"author","urls":{"Paper":"http://www.nejm.org/doi/full/10.1056/NEJMoa041588"},"downloads":0},"search_terms":["multigene","assay","predict","recurrence","tamoxifen","treated","node","negative","breast","cancer","paik","shak","tang","kim","baker","cronin","baehner","walker","watson","park","hiller","fisher","wickerham","bryant","wolmark"],"keywords":[],"authorIDs":[],"dataSources":["Bn7xRaKMY43f7hFwh"]}